Positron emission tomography imaging of atherosclerosis

Theranostics

Volumn 3, Issue 11, 2013, Pages 894-902

  Orbay, Hakan ^a   Hong, Hao ^a   Zhang, Yin ^b   Cai, Weibo ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Molecular imaging; Positron emission tomography (PET); Vulnerable plaques

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; LOW DENSITY LIPOPROTEIN RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR C; PHOSPHATIDYLCHOLINE; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; ISOTOPE LABELING; LIPOGENESIS; MACROPHAGE; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; CARDIOVASCULAR DISEASES.; EARLY DIAGNOSIS; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY (PET); VULNERABLE PLAQUES;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES.; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY (PET); VULNERABLE PLAQUES;

ATHEROSCLEROSIS; EARLY DIAGNOSIS; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84901393311     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5506     Document Type: Review

References (96)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-71.
2. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109: III27-32.
3. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006; 47: C7-12.
4. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med. 2004; 45: 1898-907.
5. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996; 94: 2013-20.
6. Wu JC, Bengel FM, Gambhir SS. Cardiovascular molecular imaging. Radiology. 2007; 244: 337-55.
7. Galbraith JE, Murphy ML, de Soyza N. Coronary angiogram interpretation. Interobserver variability. JAMA. 1978; 240: 2053-6.
8. Leape LL, Park RE, Bashore TM, Harrison JK, Davidson CJ, Brook RH. Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures. Am Heart J. 2000; 139: 106-13.
9. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001; 103: 604-16.
10. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002; 32: 70-6.
11. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res. 2011; 108: 593-606.
12. Lucignani G, Schafers M. PET, CT and MRI characterisation of the atherosclerotic plaque. Eur J Nucl Med Mol Imaging. 2010; 37: 2398-402.
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992; 326: 242-50.
14. Yucel EK, Anderson CM, Edelman RR, Grist TM, Baum RA, Manning WJ, et al. AHA scientific statement. Magnetic resonance angiography: update on applications for extracranial arteries. Circulation. 1999; 100: 2284-301.
15. Tearney GJ, Yabushita H, Houser SL, Aretz HT, Jang IK, Schlendorf KH, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation. 2003; 107: 113-9.
16. Raggi P. Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery disease. Am J Cardiol. 2001; 87: 27A-34A.
17. 18F-FDG PET and a whole lot more. J Nucl Med Technol. 2009; 37: 151-61.
18. Wong ST. Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm. 2009; 66: S9-S14.
19. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med. 2007; 13: 183-91.
20. Schillaci O, Danieli R, Padovano F, Testa A, Simonetti G. Molecular imaging of atheroslerotic plaque with nuclear medicine techniques. Int J Mol Med. 2008; 22: 3-7.
21. Erbel R, Ge J, Bockisch A, Kearney P, Gorge G, Haude M, et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. Eur Heart J. 1996; 17: 880-9.
22. Deshpande N, Needles A, Willmann JK. Molecular ultrasound imaging: current status and future directions. Clin Radiol. 2010; 65: 567-81.
23. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010; 65: 500-16.
24. Cavalcanti Filho JL, de Souza Leao Lima R, de Souza Machado Neto L, Kayat Bittencourt L, Domingues RC, da Fonseca LM. PET/CT and vascular disease: current concepts. Eur J Radiol. 2011; 80: 60-7.
25. Yoshinaga K, Manabe O, Tamaki N. Assessment of coronary endothelial function using PET. J Nucl Cardiol. 2011; 18: 486-500.
26. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997; 80: 10F-9F.
27. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012; 92: 897-965.
28. Bhargava P, He G, Samarghandi A, Delpassand ES. Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine. Am J Nucl Med Mol Imaging. 2012; 2: 221-31.
29. Cai W, Zhang Y, Kamp TJ. Imaging of induced pluripotent stem cells: from cellular reprogramming to transplantation. Am J Nucl Med Mol Imaging. 2011; 1: 18-28.
30. Huang X, Lee S, Chen X. Design of "smart" probes for optical imaging of apoptosis. Am J Nucl Med Mol Imaging. 2011; 1: 3-17.
31. Thorek DLJ, Robertson R, Bacchus WA, Hahn J, Rothberg J, Beattie BJ, et al. Cerenkov imaging-a new modality for molecular imaging. Am J Nucl Med Mol Imaging. 2012; 2: 163-73.
32. Yigit MV, Medarova Z. In vivo and ex vivo applications of gold nanoparticles for biomedical SERS imaging. Am J Nucl Med Mol Imaging. 2012; 2: 232-41.
33. Zeman MN, Scott PJH. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging. 2012; 2: 174-220.
34. Zhang Y, Cai W. Molecular imaging of insulin-like growth factor 1 receptor in cancer. Am J Nucl Med Mol Imaging. 2012; 2: 248-59.
35. Owen DR, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu Rev Med. 2011; 62: 25-40.
36. Glaudemans AW, Slart RH, Bozzao A, Bonanno E, Arca M, Dierckx RA, et al. Molecular imaging in atherosclerosis. Eur J Nucl Med Mol Imaging. 2010; 37: 2381-97.
37. Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J Nucl Med. 2010; 51 Suppl 1: 51S-65S.
38. Motz JT, Fitzmaurice M, Miller A, Gandhi SJ, Haka AS, Galindo LH, et al. In vivo Raman spectral pathology of human atherosclerosis and vulnerable plaque. J Biomed Opt. 2006; 11: 021003.
39. Kim DE, Kim JY, Schellingerhout D, Kim EJ, Kim HK, Lee S, et al. Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vasc Biol. 2010; 30: 449-56.
40. Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007; 48: 18N, 21N.
41. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007; 244: 39-47.
42. 18F-based radiotracers. Am J Nucl Med Mol Imaging. 2012; 2: 55-76.
43. Cai W, Hong H. Peptoid and positron emission tomography: an appealing combination. Am J Nucl Med Mol Imaging. 2011; 1: 76-9.
44. 18F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Imaging. 2012; 2: 110-21.
45. 18F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging. 2011; 1: 47-53.
46. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, et al. The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging. 2012; 2: 33-47.
47. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging. 2011; 1: 63-4.
48. Vach W, Høilund-Carlsen PF, Fischer BM, Gerke O, Weber W. How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging. 2011; 1: 54-62.
49. 131I-Ama monoclonal antibody in atherosclerotic rabbits. Nucl Med Biol. 1995; 22: 693-7.
50. 18F-FDG PET. Arterioscler Thromb Vasc Biol. 2008; 28: 1311-7.
51. Van Craeyveld E, Gordts SC, Singh N, Jacobs F, De Geest B. A critical reassessment of murine and rabbit models of atherosclerosis: focus on lesion progression and remodelling. Acta Cardiol. 2012; 67: 11-21.
52. Vallabajosula S MK, Knesaurek J. Imaging atherosclerotic macrophage density by positron emission tomography using F-18-flurodeoxyglucose (FDG) [abstract]. J Nucl Med Technol. 1996; 37(suppl): 38P.
53. Lederman RJ, Raylman RR, Fisher SJ, Kison PV, San H, Nabel EG, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun. 2001; 22: 747-53.
54. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-11.
55. 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009; 50: 563-8.
56. Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008; 35: 562-9.
57. Alexanderson E, Slomka P, Cheng V, Meave A, Saldana Y, Garcia-Rojas L, et al. Fusion of positron emission tomography and coronary computed tomographic angiography identifies fluorine 18 fluorodeoxyglucose uptake in the left main coronary artery soft plaque. J Nucl Cardiol. 2008; 15: 841-3.
58. Li Y, Berenji GR, Shaba WF, Tafti B, Yevdayev E, Dadparvar S. Association of vascular fluoride uptake with vascular calcification and coronary artery disease. Nucl Med Commun. 2012; 33: 14-20.
59. Laurberg JM, Olsen AK, Hansen SB, Bottcher M, Morrison M, Ricketts SA, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation. Atherosclerosis. 2007; 192: 275-82.
60. 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis. 2010; 211: 136-40.
61. Riou LM, Broisat A, Dimastromatteo J, Pons G, Fagret D, Ghezzi C. Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview. Curr Med Chem. 2009; 16: 1499-511.
62. Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis. 2007; 192: 453-4; author reply 1-2.
63. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol. 2011; 58: 603-14.
64. Boggs KP, Rock CO, Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem. 1995; 270: 7757-64.
65. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol. 2006; 26: 584-9.
66. Laitinen IE, Luoto P, Nagren K, Marjamaki PM, Silvola JM, Hellberg S, et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med. 2010; 51: 798-802.
67. Kato K, Schober O, Ikeda M, Schafers M, Ishigaki T, Kies P, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36: 1622-8.
68. 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009; 2: 331-8.
69. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006; 47: 763-9.
70. Langer HF, Haubner R, Pichler BJ, Gawaz M. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol. 2008; 52: 1-12.
71. Pietzsch J, Bergmann R, Wuest F, Pawelke B, Hultsch C, van den Hoff J. Catabolism of native and oxidized low density lipoproteins: in vivo insights from small animal positron emission tomography studies. Amino Acids. 2005; 29: 389-404.
72. Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, et al. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010; 51: 85-91.
73. Liu Y, Pressly ED, Abendschein DR, Hawker CJ, Woodard GE, Woodard PK, et al. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011; 52: 1956-63.
74. Derlin T, Habermann CR, Lengyel Z, Busch JD, Wisotzki C, Mester J, et al. Feasibility of 11C-acetate PET/CT for imaging of fatty acid synthesis in the atherosclerotic vessel wall. J Nucl Med. 2011; 52: 1848-54.
75. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001; 12: 383-9.
76. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001; 107: 1209-10.
77. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009; 2: 1213-22.
78. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008; 117: 379-87.
79. Silvola JM, Laitinen I, Sipila HJ, Laine VJ, Leppanen P, Yla-Herttuala S, et al. Uptake of 68gallium in atherosclerotic plaques in LDLR-/-ApoB100/100 mice. EJNMMI Res. 2011; 1: 14.
80. Yano Y, Budinger TF, Ebbe SN, Mathis CA, Singh M, Brennan KM, et al. Gallium-68 lipophilic complexes for labeling platelets. J Nucl Med. 1985; 26: 1429-37.
81. Gaemperli O, Shalhoub J, Owen DR, Lamare F, Johansson S, Fouladi N, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J. 2012;33:1902-10.
82. Elmaleh DR, Fischman AJ, Tawakol A, Zhu A, Shoup TM, Hoffmann U, et al. Detection of inflamed atherosclerotic lesions with diadenosine-5',5'''-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography. Proc Natl Acad Sci U S A. 2006; 103: 15992-6.
83. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74.
84. Wang Y, Vidan E, Bergman GW. Cardiac motion of coronary arteries: variability in the rest period and implications for coronary MR angiography. Radiology. 1999; 213: 751-8.
85. Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-Moller A, Dinges J, Schwaiger M, et al. PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg. 2012; 70: 473-83.
86. Zaidi H, Del Guerra A. An outlook on future design of hybrid PET/MRI systems. Med Phys. 2011; 38: 5667-89.
87. Beheshti M, Saboury B, Mehta NN, Torigian DA, Werner T, Mohler E, et al. Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept. Hell J Nucl Med. 2011; 14: 114-20.
88. 18F-fluoride PET/CT: will this become a clinical reality and a challenge to CT calcification scoring? Eur J Nucl Med Mol Imaging. 2012; 39: 660-4.
89. Piao M, Tokunaga O. Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006; 13: 82-9.
90. Luque A, Turu M, Juan-Babot O, Cardona P, Font A, Carvajal A, et al. Overexpression of hypoxia/inflammatory markers in atherosclerotic carotid plaques. Front Biosci. 2008; 13: 6483-90.
91. Luque A, Slevin M, Turu MM, Juan-Babot O, Badimon L, Krupinski J. CD105 positive neovessels are prevalent in early stage carotid lesions, and correlate with the grade in more advanced carotid and coronary plaques. J Angiogenes Res. 2009; 1: 6.
92. Pelliccia F, Cianfrocca C, Rosano G, Mercuro G, Speciale G, Pasceri V. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. JACC Cardiovasc Interv. 2010; 3: 78-86.
93. Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, et al. Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm. 2012; 9: 645-53.
94. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One. 2011; 6: e28005.
95. Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012; 39: 138-48.
96. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011; 38: 1335-43.